{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T06:14:33Z","timestamp":1778739273599,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00428-025-04386-x","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T15:35:17Z","timestamp":1769182517000},"page":"1049-1057","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Validation of IHC4\u2009+\u2009C for male breast cancer"],"prefix":"10.1007","volume":"488","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4303-9776","authenticated-orcid":false,"given":"Carmen","family":"van der Pol","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"de Hond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dieuwke Mink","family":"van der Molen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quirine","family":"Manson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inne","family":"Borel-Rinkes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arjen","family":"Witkamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elsken","family":"van der Wall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Verkooijen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"van Diest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"4386_CR1","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ejca.2017.01.034","volume":"82","author":"MA Vermeulen","year":"2017","unstructured":"Vermeulen MA, Slaets L, Cardoso F, Giordano SH, Tryfonidis K, van Diest PJ et al (2017) Pathological characterisation of male breast cancer: results of the EORTC 10085\/TBCRC\/BIG\/NABCG international male breast cancer program. Eur J Cancer 82:219\u2013227. https:\/\/doi.org\/10.1016\/j.ejca.2017.01.034","journal-title":"Eur J Cancer"},{"key":"4386_CR2","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/annonc\/mdx651","volume":"29","author":"F Cardoso","year":"2018","unstructured":"Cardoso F, Bartlett JMS, Slaets L, van Deurzen CHM, van Leeuwen-Stok E, Porter P et al (2018) Characterization of male breast cancer: results of the EORTC 10085\/TBCRC\/BIG\/NABCG international male breast cancer program. Ann Oncol 29:405\u2013417. https:\/\/doi.org\/10.1093\/annonc\/mdx651","journal-title":"Ann Oncol"},{"key":"4386_CR3","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1111\/j.1365-2559.2012.04330.x","volume":"61","author":"R Kornegoor","year":"2012","unstructured":"Kornegoor R, Verschuur-Maes AHJ, Buerger H, Hogenes MC, de Bruin PC, Oudejans JJ et al (2012) Immunophenotyping of male breast cancer. Histopathology 61:1145\u20131155. https:\/\/doi.org\/10.1111\/j.1365-2559.2012.04330.x","journal-title":"Histopathology"},{"key":"4386_CR4","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/modpathol.2011.174","volume":"25","author":"R Kornegoor","year":"2012","unstructured":"Kornegoor R, Verschuur-Maes AHJ, Buerger H, Hogenes MCH, de Bruin PC, Oudejans JJ et al (2012) Molecular subtyping of male breast cancer by immunohistochemistry. Mod Pathol 25:398\u2013404. https:\/\/doi.org\/10.1038\/modpathol.2011.174","journal-title":"Mod Pathol"},{"key":"4386_CR5","doi-asserted-by":"publisher","first-page":"e60138","DOI":"10.1371\/journal.pone.0060138","volume":"8","author":"MM Lacle","year":"2013","unstructured":"Lacle MM, van der Pol C, Witkamp A, van der Wall E, van Diest PJ (2013) Prognostic value of mitotic index and Bcl2 expression in male breast cancer. PLoS One 8:e60138. https:\/\/doi.org\/10.1371\/journal.pone.0060138","journal-title":"PLoS One"},{"key":"4386_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00633-7","volume":"24","author":"S Chatterji","year":"2023","unstructured":"Chatterji S, Krzoska E, Thoroughgood CW, Saganty J, Liu P, Elsberger B et al (2023) Defining genomic, transcriptomic, proteomic, epigenetic, and phenotypic biomarkers with prognostic capability in male breast cancer: a systematic review. Lancet Oncol 24:e74-85. https:\/\/doi.org\/10.1016\/S1470-2045(22)00633-7","journal-title":"Lancet Oncol"},{"key":"4386_CR7","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s10549-016-3991-9","volume":"160","author":"CC van der Pol","year":"2016","unstructured":"van der Pol CC, Lacle MM, Witkamp AJ, Kornegoor R, Miao H, Bouchardy C et al (2016) Prognostic models in male breast cancer. Breast Cancer Res Treat 160:339\u2013346. https:\/\/doi.org\/10.1007\/s10549-016-3991-9","journal-title":"Breast Cancer Res Treat"},{"key":"4386_CR8","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.steroids.2011.02.032","volume":"76","author":"M Dowsett","year":"2011","unstructured":"Dowsett M, Salter J, Zabaglo L, Mallon E, Howell A, Buzdar AU et al (2011) Predictive algorithms for adjuvant therapy: TransATAC. Steroids 76:777\u2013780. https:\/\/doi.org\/10.1016\/j.steroids.2011.02.032","journal-title":"Steroids"},{"key":"4386_CR9","doi-asserted-by":"publisher","unstructured":"Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer. J Clin Oncol 2011;29:4273\u20138. https:\/\/doi.org\/10.1200\/JCO.2010.31.2835","DOI":"10.1200\/JCO.2010.31.2835"},{"key":"4386_CR10","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw149","volume":"108","author":"R Buus","year":"2016","unstructured":"Buus R, Sestak I, Kronenwett R, Denkert C, Dubsky P, Krappmann K et al (2016) Comparison of EndoPredict and EPclin with Oncotype DX recurrence score for prediction of risk of distant recurrence after endocrine therapy. J Natl Cancer Inst 108:djw149. https:\/\/doi.org\/10.1093\/jnci\/djw149","journal-title":"J Natl Cancer Inst"},{"key":"4386_CR11","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1093\/bioinformatics\/btr597","volume":"28","author":"DJ Stekhoven","year":"2012","unstructured":"Stekhoven DJ, B\u00fchlmann P (2012) MissForest \u2014 non-parametric missing value imputation for mixed-type data. Bioinformatics 28:112\u2013118. https:\/\/doi.org\/10.1093\/bioinformatics\/btr597","journal-title":"Bioinformatics"},{"key":"4386_CR12","doi-asserted-by":"publisher","unstructured":"Guo C, Yang Y, Chen Y (2021) The optimal machine learning-based missing data imputation for the cox proportional hazard model 9:1\u20138. https:\/\/doi.org\/10.3389\/fpubh.2021.680054","DOI":"10.3389\/fpubh.2021.680054"},{"key":"4386_CR13","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1016\/j.cjca.2020.11.010","volume":"37","author":"PC Austin","year":"2021","unstructured":"Austin PC, White IR, Lee DS, van Buuren S (2021) Missing data in clinical research: a tutorial on multiple imputation. Can J Cardiol 37:1322\u20131331. https:\/\/doi.org\/10.1016\/j.cjca.2020.11.010","journal-title":"Can J Cardiol"},{"key":"4386_CR14","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1093\/aje\/kwaa225","volume":"190","author":"C Leyrat","year":"2021","unstructured":"Leyrat C, Carpenter JR, Bailly S, Williamson EJ (2021) Common methods for handling missing data in marginal Leyrat C, Carpenter JR, Bailly S, Williamson EJ. common methods for handling missing data in marginal structural models: what works and why. Am J Epidemiol 190:663\u2013672. https:\/\/doi.org\/10.1093\/aje\/kwaa225","journal-title":"Am J Epidemiol"},{"key":"4386_CR15","doi-asserted-by":"publisher","first-page":"i4338","DOI":"10.1136\/bmj.i4338","volume":"354","author":"M Lamain-de Ruiter","year":"2016","unstructured":"Lamain-de Ruiter M, Kwee A, Naaktgeboren CA, de Groot I, Evers IM, Groenendaal F et al (2016) External validation of prognostic models to predict risk of gestational diabetes mellitus in one Dutch cohort: prospective multicentre cohort study. BMJ 354:i4338. https:\/\/doi.org\/10.1136\/bmj.i4338","journal-title":"BMJ"},{"key":"4386_CR16","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1177\/0272989X06295361","volume":"26","author":"AJ Vickers","year":"2006","unstructured":"Vickers AJ, Elkin EB (2006) Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making 26:565\u2013574. https:\/\/doi.org\/10.1177\/0272989X06295361","journal-title":"Med Decis Making"},{"key":"4386_CR17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-2288-13-33","volume":"13","author":"P Royston","year":"2013","unstructured":"Royston P, Altman DG (2013) External validation of a Cox prognostic model: principles and methods. BMC Med Res Methodol 13:33. https:\/\/doi.org\/10.1186\/1471-2288-13-33","journal-title":"BMC Med Res Methodol"},{"key":"4386_CR18","doi-asserted-by":"publisher","unstructured":"Velde CJH Van De, Hasenburg A, Kieback DG, Putter H (2016) Validation of the IHC4 breast cancer prognostic algorithm using multiple approaches on the multinational TEAM clinical trial. https:\/\/doi.org\/10.5858\/arpa.2014-0599-OA","DOI":"10.5858\/arpa.2014-0599-OA"},{"key":"4386_CR19","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1159\/000362281","volume":"86","author":"YH Park","year":"2014","unstructured":"Park YH, Im SA, Cho EY, Ahn JH, Woo SY, Kim S et al (2014) Validation and comparison of CS-IHC4 scores with a nomogram to predict recurrence in hormone receptor-positive breast cancers. Oncology 86:279\u2013288. https:\/\/doi.org\/10.1159\/000362281","journal-title":"Oncology"},{"key":"4386_CR20","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1136\/jclinpath-2015-203212","volume":"69","author":"A Dodson","year":"2016","unstructured":"Dodson A, Zabaglo L, Yeo B, Miller K, Smith I, Dowsett M (2016) Risk of recurrence estimates with IHC4+C are tolerant of variations in staining and scoring: an analytical validity study. J Clin Pathol 69:128\u2013135. https:\/\/doi.org\/10.1136\/jclinpath-2015-203212","journal-title":"J Clin Pathol"},{"key":"4386_CR21","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/bjc.2015.222","volume":"113","author":"B Yeo","year":"2015","unstructured":"Yeo B, Zabaglo L, Hills M, Dodson A, Smith I, Dowsett M (2015) Clinical utility of the IHC4+C score in oestrogen receptor-positive early breast cancer: a prospective decision impact study. Br J Cancer 113:390\u2013395. https:\/\/doi.org\/10.1038\/bjc.2015.222","journal-title":"Br J Cancer"},{"key":"4386_CR22","doi-asserted-by":"publisher","first-page":"66","DOI":"10.5858\/arpa.2014-0599-OA","volume":"140","author":"JMS Bartlett","year":"2016","unstructured":"Bartlett JMS, Christiansen J, Gustavson M, Rimm DL, Piper T, Van De Velde CJH et al (2016) Validation of the IHC4 breast cancer prognostic algorithm using multiple approaches on the multinational TEAM clinical trial. Arch Pathol Lab Med 140:66\u201374. https:\/\/doi.org\/10.5858\/arpa.2014-0599-OA","journal-title":"Arch Pathol Lab Med"},{"key":"4386_CR23","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s10549-017-4543-7","volume":"168","author":"MCU Cheang","year":"2018","unstructured":"Cheang MCU, Bliss JM, Viale G, Speirs V, Palmieri C, Shaaban A et al (2018) Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): pathIES. Breast Cancer Res Treat 168:169\u2013178. https:\/\/doi.org\/10.1007\/s10549-017-4543-7","journal-title":"Breast Cancer Res Treat"},{"key":"4386_CR24","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1200\/JCO.2012.46.1558","volume":"31","author":"M Dowsett","year":"2013","unstructured":"Dowsett M, Sestak I, Lopez-Knowles E, Sidhu K, Dunbier AK, Cowens JW et al (2013) Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol 31:2783\u20132790. https:\/\/doi.org\/10.1200\/JCO.2012.46.1558","journal-title":"J Clin Oncol"},{"key":"4386_CR25","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s10549-017-4266-9","volume":"164","author":"A Sheri","year":"2017","unstructured":"Sheri A, Smith IE, Hills M, Jones RL, Johnston SR, Dowsett M (2017) Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer. Breast Cancer Res Treat 164:395\u2013400. https:\/\/doi.org\/10.1007\/s10549-017-4266-9","journal-title":"Breast Cancer Res Treat"},{"key":"4386_CR26","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.breast.2016.06.019","volume":"29","author":"R Lakhanpal","year":"2016","unstructured":"Lakhanpal R, Sestak I, Shadbolt B, Bennett GM, Brown M, Phillips T et al (2016) IHC4 score plus clinical treatment score predicts locoregional recurrence in early breast cancer. Breast 29:147\u2013152. https:\/\/doi.org\/10.1016\/j.breast.2016.06.019","journal-title":"Breast"},{"key":"4386_CR27","doi-asserted-by":"publisher","first-page":"e1170","DOI":"10.1634\/theoncologist.2019-1006","volume":"25","author":"L Jin","year":"2020","unstructured":"Jin L, Chen K, Tan C, Li J, Luo J, Yang Y et al (2020) Prognostic value of modified IHC4 score in patients with estrogen receptor-positive metastatic breast cancer. Oncologist 25:e1170\u2013e1180. https:\/\/doi.org\/10.1634\/theoncologist.2019-1006","journal-title":"Oncologist"},{"key":"4386_CR28","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1016\/j.humpath.2015.07.008","volume":"46","author":"JA Engelberg","year":"2015","unstructured":"Engelberg JA, Retallack H, Balassanian R, Dowsett M, Zabaglo L, Ram AA et al (2015) Score the core web-based pathologist training tool improves the accuracy of breast cancer IHC4 scoring. Hum Pathol 46:1694\u20131704. https:\/\/doi.org\/10.1016\/j.humpath.2015.07.008","journal-title":"Hum Pathol"},{"key":"4386_CR29","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1038\/s41379-019-0270-4","volume":"32","author":"M Abubakar","year":"2019","unstructured":"Abubakar M, Figueroa J, Ali HR, Blows F, Lissowska J, Caldas C et al (2019) Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer. Mod Pathol 32:1244\u20131256. https:\/\/doi.org\/10.1038\/s41379-019-0270-4","journal-title":"Mod Pathol"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-025-04386-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-025-04386-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-025-04386-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T05:58:44Z","timestamp":1778738324000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-025-04386-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["4386"],"URL":"https:\/\/doi.org\/10.1007\/s00428-025-04386-x","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"13 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}